CYP19A1 and breast carcinoma: Although the protective role of aromatase inhibitors on breast cancer due to reduced E2 concentrations is well established, the role of the concomitant increases in serum testosterone concentration has usually been overlooked, and could be further explored using genetically modified models with altered aromatase expression [90]-[93].